Cost of adult chronic rhinosinusitis: A systematic review

Smith, Kristine A.; Orlandi, Richard R.; Rudmik, Luke

doi:10.1002/lary.25180

Cited by 288 publications

(258 citation statements)

References 55 publications

Supporting

Mentioning

255

Contrasting

Unclassified

Order By: Relevance

“…According to the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS), CRS is characterized by the presence of both subjective and objective evidence of chronic sinonasal inflammation for more than 12 weeks (3) and includes several distinguished clinical entities, the most important of which are CRS with nasal polyposis (CRSwNP) and CRS without nasal polyposis (CRSsNP) (4) . CRSwNP is a debilitating disease that has a substantial impact on the patient's quality of life with its overall annual economic burden in the United States to be estimated around $22 billion in 2014 (direct and indirect costs) (5) . Despite the fact that its etiology remains elusive, CRSwNP is often associated with allergy, asthma, infection, fungi, cystic fibrosis, and aspirin sensitivity (3) .…”

Section: Introductionmentioning

confidence: 99%

Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review

Tsetsos

Goudakos

Daskalakis

et al. 2018

Rhin

View full text Add to dashboard Cite

Background: Μonoclonal antibodies have been proposed as a novel therapy in patients suffering from chronic rhinosinusitis with nasal polyposis (CRSwNP). The purpose of this systematic review was to evaluate their efficacy and safety.Methodology: A literature search was performed in MEDLINE, Web of Science, the Cochrane Library and multiple trial registries followed by extensive hand-searching for the identification of relevant studies. Only randomized controlled trials (RCTs) comparing the use of monoclonal antibodies with placebo or another therapy in adult patients with CRSwNP were included.Results: Anti-immunoglobin E (IgE) therapy with omalizumab was assessed in two studies, anti-interleukin (IL)-5 therapy in three studies (1 reslizumab, 2 mepolizumab) and finally anti-IL-4 and anti-IL-13 therapy in only one. With the exception of one study, biologic therapy was proved to be effective in reducing total nasal endoscopic polyp score (TPS) in treatment as compared to placebo groups. Monoclonal antibodies brought about improvement in several other outcomes, such as opacification in computed tomography (CT), quality of life measures, nasal airflow, olfaction and type 2 helper T-cell (Th2) associated biomarkers. Overall, the use of these agents was deemed safe and well-tolerated.Conclusions: This is the first systematic review showing encouraging results for the use of all three main categories of monoclonal antibodies in CRSwNP patients and highlights the need for further well-designed and with larger sample sizes RCTs.

show abstract

Section: Introductionmentioning

confidence: 99%

Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review

Tsetsos

Goudakos

Daskalakis

et al. 2018

Rhin

View full text Add to dashboard Cite

show abstract

“…It has a severe impact on qualityof-life and national economy [2,3]. Diagnosis is based on characteristic symptoms lasting more than 12 weeks, computed tomography (CT) scan and/or endoscopic changes [4].…”

Section: Introductionmentioning

confidence: 99%

Long-term follow-up after ESS and balloon sinuplasty: Comparison of symptom reduction and patient satisfaction

Koskinen

Myller

Mattila

et al. 2016

Acta Oto-Laryngologica

View full text Add to dashboard Cite

“…It has been estimated that in the year 2014, the costs for the treatment of patients suffering from rhinosinusitis was $6.9 to $9.9 billion. The endoscopic operation costs around $1547 to $2,00 for each patient (2). Secondary conditions may arise after the disease, which mostly include 2 categories: 1) orbital ocular (60 -75%) and 2) intracranial complications (15 -20%) (3).…”

Section: Introductionmentioning

confidence: 99%

Effect of Myrtus communis L. Syrup on Chronic Rhinosinusitis: A Randomized Double-Blind, Placebo-Controlled Pilot Study

Abrishamkar

Kamalinejad

Jafari

et al. 2017

Iran Red Crescent Med J

View full text Add to dashboard Cite

Background: According to the Iranian Traditional Medicine (ITM) resources, myrtle (Myrtus communis L.) resolves swelling, wounds and injuries; its wound exsiccation capability and tissue enforcement properties may be helpful in the treatment of the rhinosinusitis. Objectives:The objective of the current trial was to assess the effects of Myrtus communis aqueous extract in the treatment of chronic rhinosinusitis. Methods: A total of 38 patients referring to the Masih Daneshvari Hospital (Tehran, Iran) for the treatment of chronic rhinosinusitis during the year 2016 were recruited for a double-blinded randomized placebo-controlled trial. They were randomly allocated in 2 groups: 22 patients were in the treatment group and 16 patients in the placebo group. Recruitment was based on the European position paper on rhinosinusitis (EPOS). Patients' data, including demographic information, SNOT22 questionnaire scores, and visual analog scale (VAS), were gathered and recorded by an otolaryngologist. Patients were investigated with a CT scan of the paranasal sinuses at the beginning of the study. Results: A total of 13 patients (59.1%) in the treatment group were female and 7 in the placebo group (43.7%). The median age of patients in the treatment group was 38.86 (18 -68) and in the placebo group 39.93 (22 -75) years. Data analysis revealed that symptoms improved in the treatment group after treatment in most parameters, according to the SNOT-22 parameters. However, most of these

show abstract

Cost of adult chronic rhinosinusitis: A systematic review

Cited by 288 publications

References 55 publications

Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review

Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review

Long-term follow-up after ESS and balloon sinuplasty: Comparison of symptom reduction and patient satisfaction

Effect of Myrtus communis L. Syrup on Chronic Rhinosinusitis: A Randomized Double-Blind, Placebo-Controlled Pilot Study

Contact Info

Product

Resources

About